Brainsway (NASDAQ:BWAY) Announces Quarterly Earnings Results

Brainsway (NASDAQ:BWAY) issued its quarterly earnings data on Tuesday. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03), Zacks reports. The company had revenue of $13.51 million for the quarter, compared to the consensus estimate of $13.04 million. Brainsway had a return on equity of 9.65% and a net margin of 12.73%. Brainsway updated its FY 2025 guidance to EPS.

Brainsway Stock Up 4.0%

NASDAQ:BWAY opened at $15.78 on Thursday. The company has a market cap of $299.82 million, a P/E ratio of 52.60 and a beta of 1.22. Brainsway has a twelve month low of $7.84 and a twelve month high of $17.92. The business has a 50 day moving average price of $15.82 and a two-hundred day moving average price of $13.20.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 17th. Northland Securities upped their target price on shares of Brainsway from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Brainsway in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Brainsway in a research note on Monday, August 25th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Institutional Investors Weigh In On Brainsway

A hedge fund recently raised its stake in Brainsway stock. NewEdge Advisors LLC lifted its position in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 61.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,828 shares of the company’s stock after buying an additional 7,549 shares during the quarter. NewEdge Advisors LLC owned about 0.11% of Brainsway worth $188,000 as of its most recent SEC filing. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.